Advise the patient to read the FDA-approved patient labeling (
Efficacy Based on Animal Models Alone
Inform patients that the efficacy of TEMBEXA is based solely on efficacy studies demonstrating a survival benefit in animals and that the effectiveness of TEMBEXA has not been tested in humans with smallpox disease
Elevations of Hepatic Transaminases and Bilirubin
Inform patients of the need for liver monitoring before treatment with TEMBEXA and during treatment if signs or symptoms of liver injury occur. Advise patients to report symptoms that may indicate liver injury, including right upper abdominal discomfort, dark urine, or jaundice
Diarrhea and Other Gastrointestinal Adverse Events
Inform patients of the risk of diarrhea and other GI adverse events (nausea, vomiting, and abdominal pain) while taking TEMBEXA. Advise patients to inform their healthcare provider if they develop severe diarrhea or other severe GI symptoms
Important Drug Interactions
Inform patients that TEMBEXA may interact with some drugs. If concomitant use of OATP1B1 and 1B3 inhibitors with TEMBEXA is necessary, advise patients to postpone the dosing of these medicines for at least 3 hours after TEMBEXA administration
Embryo-fetal Toxicity
Advise pregnant individuals and individuals of childbearing potential of the risk to a fetus and to inform their healthcare provider of a known or suspected pregnancy. Advise individuals of childbearing potential to use effective contraception during treatment with TEMBEXA and for at least 2 months after the last dose. Due to animal findings of testicular toxicity, advise individuals of reproductive potential with partners of childbearing potential to use condoms during treatment with TEMBEXA and for at least 4 months after the last dose
Infertility
Advise individuals of reproductive potential that treatment with TEMBEXA may deplete sperm, resulting in infertility
Lactation
Instruct individuals with smallpox not to breastfeed their infant because of the risk of passing variola virus to the breastfed infant
Important Administration Instructions for Oral Suspension
Instruct patients or caregivers to use an oral dosing syringe to correctly measure the prescribed amount of medication. Oral dosing syringes may be obtained from the pharmacy. Refer to instructions above for administration of TEMBEXA oral suspension through enteral tubes
Advise patients taking the oral suspension to discard unused portion after completion of the 2 prescribed doses.
Handling
Advise patients not to divide, break, or crush tablets. Advise patients to avoid direct contact with broken or crushed tablets and oral suspension. If contact with skin or mucous membranes occurs, inform patients to wash thoroughly with soap and water, and rinse eyes thoroughly with water
Manufactured for Emergent BioDefense
3500 North Martin Luther King Jr Blvd